Neoadjuvant Mitomycin C Before TURBT May Cut NMIBC Recurrence, Progression Risks - Oncology Nurse Advisor A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.

In #NMIBC, immediate administration of 2 doses of neoadjuvant intravesical mitomycin C chemotherapy prior to TURBT may reduce recurrence and progression risks compared with TURBT alone. From @renalurologynews.bsky.social.

https://bit.ly/41gINY2

#blcsm #bladdercancer

Nogapendekin Alfa Inbakicept Joins NCCN Guidelines for Papillary-Only, BCG-Unresponsive NMIBC | OncLive The NCCN guidelines in bladder cancer now include nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with papillary-only disease.

The NCCN has updated its Clinical Practice Guidelines in Oncology to include nogapendekin alfa inbakicept plus BCG as a category 2A recommendation for BCG-unresponsive NMIBC with papillary-only tumors #blcsm #oncology www.onclive.com/view/nogapen...

Ipilimumab and Nivolumab With CRT May Be a Bladder-Sparing Treatment in MIBC - Oncology Nurse Advisor The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.

Combined neoadjuvant treatment with ipilimumab and nivolumab followed by CRT shows promise as a bladder-sparing treatment for muscle-invasive #bladdercancer. From @natmed.nature.com and @renalurologynews.bsky.social.

Read more: ➡️ https://bit.ly/3MZPjiH

#MIBC #blcsm #UroOnc

K-M curves of ctDNA result

K-M curves of ctDNA as dynamic biomarker

ctDNA predicts extravesical not local disease

Summary of conclusions

@ascocancer.bsky.social #GU26 the key findings:
#blcsm

Dr. Ghatalia giving talk of LBA at general session

The protocol schema for ph2 single-arm RETAIN-2 trial

@ascocancer.bsky.social A major late breaking abstract from Fox Chase: ctDNA informing outcome and prognosis for MIBC post-NAT and is a key parameter for risk-adapted management
An amazing presentation by Dr. Ghatalia, worth reviewing the recording again
#blcsm

Thomas Powles, MD, MBBS, MRCP, discusses implication of ctDNA data from the IMvigor011 trial and evolving strategies in MIBC @ascocancer.bsky.social #GU26 #blcsm #oncology www.onclive.com/shorts/explo...

Recurrence following EV/P v Cis/Gem

OS results for EV/P v Cis/Gem

#GU26 @ascocancer.bsky.social
Keynote-B15 results—significantly improves RFS/OS compared to Gem/Cis
#blcsm

Galsky at the podium at GU ASCO Day 2

Keynote-B15 Protocol schema

Protocol pathway and results

#GU26 @ascocancer.bsky.social
Starting off with practice changing presentation of Keynote-B15:

Galsky reporting the unprecedented response surpassing Cis-Platin for NeoAdjuvant Treatment, this will cement EV/P as SOC for all MIBC
#blcsm

Retrospective data show up-front dose reductions of enfortumab vedotin lowered the risk of treatment interruptions without impeding OS in patients with advanced urothelial cancer receiving first-line enfortumab vedotin plus pembrolizumab #blcsm #oncology #OncClub www.onclive.com/view/enfortu...

Real-World Analysis Supports Rethinking Upfront Dose Intensity of Enfortumab Vedotin in Advanced Urothelial Cancer @rsedhom.bsky.social @pennmedicine.bsky.social #blcsm www.onclive.com/view/real-wo...

GDF-15 Blockade May Deepen Neoadjuvant IO Response in Cisplatin-Ineligible MIBC @myesmo.bsky.social #blcsm #oncology www.onclive.com/view/gdf-15-...

FDA Approval of Perioperative Enfortumab Vedotin Plus Pembrolizumab Redefines Cisplatin-Ineligible MIBC Care @fda.gov #blcsm #oncology
www.onclive.com/view/fda-app...

Nogapendekin Alfa Inbakicept Plus BCG Yields Significant DOR in BCG-Naive NMIBC
#blcsm #oncology
www.onclive.com/view/nogapen...

utDNA and ctDNA Are Predictive of Residual Disease After TAR-200 in MIBC | OncLive Andrea Necchi, MD, dives into the details of the SunRISe-4 trial findings, implications, and ways that utDNA and ctDNA may operate as biomarkers in MIBC.

utDNA and ctDNA Are Predictive of Residual Disease After TAR-200 in MIBC
#blcsm #oncology
www.onclive.com/view/utdna-a...

#BCG may be less effective in patients who develop metachronous #NMIBC after radical nephrouretectomy for #UTUC. Reported at #SUO25 by Yu Guang Tan, MBBS, of Singapore General Hospital covered by @renalurologynews.bsky.social.
https://bit.ly/4sJXtf5

#bladdercancer #blcsm

SunRISe-4: Neoadjuvant Intravesical Gemcitabine Plus Cetrelimab Shows Promise in Muscle-Invasive Bladder Cancer Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic complete response in this population.

Neoadjuvant treatment with a gemcitabine intravesical system plus the PD-1 blocking antibody cetrelimab outperformed cetrelimab alone in patients with muscle-invasive #bladdercancer. Published in @ascopost.bsky.social Journal of Clinical Oncology.

https://bit.ly/4j2SvFL

#blcsm #MIBC

BREAKING 🚨: @fda.gov Approves Niraparib/Abiraterone Acetate Plus Prednisone for BRCA2+ mCSPC

Learn more here 📰: www.onclive.com/view/fda-app...

#blcsm #oncology #FDAapproved

Adjuvant Atezolizumab Generates DFS, OS Benefit Regardless of Tumor Size, Nodal Status, and Prior NAC in ctDNA+ MIBC | OncLive Findings from an exploratory analysis of IMvigor011 support the use of serial ctDNA testing to guide atezolizumab use in MIBC.

Adjuvant Atezolizumab Generates DFS, OS Benefit Regardless of Tumor Size, Nodal Status, and Prior NAC in ctDNA+ MIBC #SUO2025 #blcsm www.onclive.com/view/adjuvan...

Adjuvant Radiotherapy Improves Locoregional Recurrence in High-Risk MIBC - Oncology Nurse Advisor In patients with locally advanced muscle-invasive bladder cancer who have undergone radical cystectomy and chemotherapy, adjuvant radiotherapy improves survival outcomes compared to observation only.

In patients with high-risk #MIBC, the 2-year locoregional failure-free survival rate was 87.1% with radiotherapy and 76.0% with observation. From @cancertherapyadv.bsky.social.

https://bit.ly/499ZqtR

#blcsm #bladdercancer

EV-103 Cohort K: long-term outcomes of EV ± pembrolizumab in la/mUC - VJOncology Terence Friedlander, MD, University of California, San Francisco, CA, discusses updated results from Cohort K of the Phase Ib/II EV-103...

Terence Friedlander, MD, shares 3.5-year #EV103 Cohort K data at #ESMO25 — enfortumab vedotin + pembrolizumab continues to show durable responses & survival benefits in 1L la/mUC.

🎥 Watch: buff.ly/kWn5KkI

#UroOnc #UroSoMe #Blcsm #ImmunoOnc #CTSM #TrialUpdate

ESMO 2025: Novel Combinations Are Changing Standards of Care in Bladder Cancer ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

Phase 3 data from multiple studies presented at #ESMO25 demonstrated that novel staging approaches along with new therapy combinations, such as EV plus pembrolizumab and disitamab vedotin plus toripalimab improved SO in patients with #bladdercancer.

https://bit.ly/4qMWKsC

#blcsm #UroOnc

FORAGER-1: dose optimization of LY3866288 in FGFR3-altered tumors - VJOncology Alexandra Drakaki, MD, PhD, University of California, Los Angeles, CA, discusses the Phase I FORAGER-1 study (NCT05614739) of LY3866288, a...

Alexandra Drakaki, MD, PhD, discusses FORAGER-1 testing LY3866288 in FGFR3-altered tumors

🧬 200 mg BID = well tolerated
💥 Encouraging antitumor activity in mUC
🧪 Activity seen post-FGFR inhibitor exposure

🎥 buff.ly/ozWqgdG

#BladderCancer #Blcsm #UroOnc #UroSoMe #CTSM #TrialUpdate #ESMO25

Serial ctDNA Testing Holds Potential to Further Personalize MIBC Management | OncLive Joaquim Bellmunt, MD, PhD, discusses ways that ctDNA tests could augment bladder cancer management and the need for confirmatory data from ongoing trials.

Serial ctDNA Testing Holds Potential to Further Personalize MIBC Management @danafarber.bsky.social #blcsm #oncology www.onclive.com/view/serial-...

CheckMate 274: 5-year results of adjuvant nivolumab in MIUC - VJOncology Clara Steiner, MD, Dana-Farber Cancer Institute, Boston, MA & University Hospital Leipzig, Leipzig, Germany, gives an overview of updated 5-year...

At #ESMO25, Clara Steiner, MD, presents 5-year results of CheckMate 274 in MIUC

💊 Adjuvant nivolumab vs placebo after surgery
📈 Sustained DFS, OS & disease-specific survival benefit
🧫 ctDNA-positive pts saw enhanced benefit
✅ No new safety concerns

🎥 Watch: buff.ly/ou4EvLv

#UroOnc #UroSoMe #Blcsm

In MIBC patients, ctDNA-guided, adjuvant atezolizumab treatment is associated with significant survival improvements over placebo. Presented at #ESMO25 by Dr Thomas Powles of
@qmul.bsky.social. #blcsm #gucsm #ESMO2025

shorturl.at/J32bd

First-line treatment with disitamab vedotin plus toripalimab could be a new standard for patients with HER2-expressing, locally advanced or metastatic urothelial carcinoma, according to Dr Jun Guo, who presented these results at #ESMO25. #gucsm #blcsm #ESMO2025

shorturl.at/gyhIS

First-Line Disitamab Vedotin Plus Toripalimab Yields Survival Advantage in HER2+ Advanced Urothelial Cancer | OncLive Frontline disitamab vedotin plus toripalimab significantly improved PFS and OS in HER2-expressing locally advanced or metastatic urothelial carcinoma.

First-Line Disitamab Vedotin Plus Toripalimab Yields Survival Advantage in HER2+ Advanced Urothelial Cancer @myesmo.bsky.social #ESMO2025 #ESMO25 #blcsm #oncology
www.onclive.com/view/first-l...

Adding perioperative enfortumab vedotin & pembrolizumab to surgical treatment can improve response and survival outcomes in patients with MIBC who are ineligible for cisplatin, according to research presented at #ESMO25. #blcsm #gucsm #esmo2025

shorturl.at/vFYcq

Perioperative Enfortumab Vedotin Plus Pembrolizumab May Represent New SOC in Cisplatin-Ineligible MIBC | OncLive Enfortumab vedotin plus pembrolizumab significantly improved survival and pCR vs surgery alone in cisplatin-ineligible MIBC per KEYNOTE-905 data.

Perioperative Enfortumab Vedotin Plus Pembrolizumab May Represent New SOC in Cisplatin-Ineligible MIBC @myesmo.bsky.social #ESMO25 #ESMO2025 #blcsm #oncology
www.onclive.com/view/periope...

Durvalumab Plus BCG May Be New Treatment Option for BCG-Naïve, High-Risk NMIBC Adding durvalumab to induction and maintenance with Bacillus Calmette–Guérin (BCG) can improve disease-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer, data sugg...

Adding durvalumab to induction and maintenance with BCG can improve disease-free survival in patients with BCG-naïve, high-risk NMIBC, data presented at #ESMO25 by Dr Maria De Santis of Charité Universitätsmedizin Berlin suggest. #gucsm #blcsm #ESMO2025

shorturl.at/QYecx